Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritumax vs MabThera in Rheumatoid Arthritis
NCT03061838Phase 1Terminated
- Sponsor
- BioIntegrator LLC
- Start
- Oct 2016
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by BioIntegrator LLC. Primary endpoints: Area under the plasma concentration versus time curve at 24 weeks and Peak Plasma Concentration at 24 weeks. Started Oct 2016; status: terminated.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03061838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03061838.